Universitat Autònoma de Barcelona-ko ikertzaileekin lankidetzan egindako argitalpenak (18)

2024

  1. Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry

    Therapeutic Advances in Gastroenterology, Vol. 17

  2. Evaluation of Genetic Variants Associated with the Risk of Thiopurine-Related Pancreatitis: A Case Control Study from ENEIDA Registry

    Digestive Diseases, Vol. 42, Núm. 3, pp. 257-264

  3. Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 5, pp. 604-612

  4. Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA

    Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 11, pp. 2280-2290

  5. Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA

    Pharmaceutics, Vol. 16, Núm. 5

2022

  1. Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU

    Journal of Clinical Medicine, Vol. 11, Núm. 13

2021

  1. Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry

    Journal of Hepatology, Vol. 75, Núm. 1, pp. 86-97

  2. We report a patient who presented intrahepatic cholangitis and cholecystitis after SARS-CoV-2 infection

    Journal of Gastroenterology and Hepatology (Australia), Vol. 36, Núm. 8, pp. 2037

2020

  1. Clinical validation of risk scoring systems to predict risk of delayed bleeding after EMR of large colorectal lesions

    Gastrointestinal Endoscopy, Vol. 91, Núm. 4, pp. 868-878.e3

2019

  1. Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study

    Journal of Crohn's & colitis, Vol. 13, Núm. 12, pp. 1492-1500

  2. Nivolumab-induced immune-mediated colitis: an ulcerative colitis look-alike—report of new cases and review of the literature

    International Journal of Colorectal Disease, Vol. 34, Núm. 5, pp. 861-865

2018

  1. Long-term safety of in utero exposure to anti-TNFα drugs for the treatment of inflammatory bowel disease: Results from the multicenter European TEDDY study

    American Journal of Gastroenterology, Vol. 113, Núm. 3, pp. 396-403

2017

  1. Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients

    Journal of Gastroenterology, Vol. 52, Núm. 7, pp. 788-799

  2. Erratum to: Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients (J Gastroenterol, 10.1007/s00535-016-1274-1)

    Journal of Gastroenterology

2016

  1. Resultados en la práctica clínica del tratamiento de la hepatitis crónica por virus B con tenofovir y entecavir

    Infectio, Vol. 20, Núm. 3, pp. 123-129

2015

  1. Effectiveness of adalimumab in perianal fistulas in Crohn's disease patients naive to Anti-TNF therapy

    Journal of Clinical Gastroenterology, Vol. 49, Núm. 1, pp. 34-40

2014

  1. Risk of colectomy in patients with ulcerative colitis under thiopurine treatment

    Journal of Crohn's and Colitis, Vol. 8, Núm. 10, pp. 1287-1293

2013

  1. Hepatotoxicidad de rizatriptán. Descripción de un caso clínico

    Gastroenterologia y Hepatologia, Vol. 36, Núm. 4, pp. 261-263